Proxygen will receive an up front & will be eligible to receive ~$2.55B upon achievement of specified research, development, and commercial milestones across all programs along with royalties on net sales of any such products
The collaboration combines Proxygen’s platform technology and unique expertise with MSD’s class research and development capabilities to identify novel molecular glue degraders
Proxygen maintains multiple partnerships incl. collaboration with Boehringer Ingelheim and Merck KGaA to work together to co-create synergies along the drug development pipeline as it advances its internal programs toward clinical development
Ref: Globenewswire | Image: Proxygen
Related New:- Simcere Zaiming Entered into a Clinical Collaboration Agreement with MSD to Evaluate SIM0235 + Keytruda for Advanced Solid Tumors and Cutaneous T-cell Lymphoma
